Ecstasy-induced psychotic disorder: Six-month follow-up study

European Addiction Research

Volumn 8, Issue 3, 2002, Pages 133-140

  Landabaso, M A ^a   Iraurgi, I ^b,e   Jimenez Lerma J M ^c   Calle, R ^a   Sanz, J ^a   Gutierrez Fraile M ^d  

^a Drug Addiction Center   (Spain)

^b Rekalde Psychosocial Health Care Module   (Spain)

^c Drug Addiction Treatment Center   (Spain)

^d HOSPITAL DE CRUCES   (Spain)

^e Módulo de Asistencia Psicosocial de Rekalde ^*  (Spain)

Author keywords

Atypical neuroleptics; Drug induced psychotic disorder; Ecstasy; Olanzapine; Symptoms

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; OLANZAPINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DELUSION; DEPRESSION; DIAGNOSTIC PROCEDURE; DISEASE SEVERITY; DRUG DEPENDENCE; DRUG EFFICACY; DRUG USE; FEMALE; FOLLOW UP; HALLUCINATION; HUMAN; INCIDENCE; MALE; MENTAL DISEASE; NEGATIVE SYNDROME; OUTPATIENT DEPARTMENT; PRIORITY JOURNAL; PSYCHOSIS; STATISTICAL SIGNIFICANCE; TIME; TREATMENT INDICATION;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; FEMALE; FOLLOW-UP STUDIES; HALLUCINOGENS; HUMANS; MALE; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; PIRENZEPINE; PSYCHIATRIC STATUS RATING SCALES; PSYCHOSES, SUBSTANCE-INDUCED;

EID: 0036278962     PISSN: 10226877     EISSN: None     Source Type: Journal    
DOI: 10.1159/000059383     Document Type: Article

References (46)

1. Toxicity and deaths from 3,4-methylenedioxymethamphetamine ('ecstasy')
2. Aplastic anaemia following exposure to 3,4-methylene-dioxymethamphetamine ('ecstasy')
3. Agony and ecstasy: A review of MDMA effects and toxicity
4. Neuropsychiatric manifestations following the use of 3,4-methylene-dioxymethamphetamine (MDMA: 'Ecstasy')
5. 'Ecstasy' psychosis and flashbacks
6. Psychosis and recreational use of MDMA (ecstasy)
7. Chronic paranoia after misuse of MDMA ('ecstasy')
8. Diversity of psychopathology associated with the use of 3,4-methylenedioximethanphetamine ('ecstasy')
9. Chronic atypical psychosis associated with MDMA ('ecstasy') abuse
10. Psychiatric complications of ecstasy use
11. Ecstasy: A case of possible drug-induced psychosis
12. Persisting and late onset psychotic disorders due to consumption of ecstasy (MDMA)
13. An 'accidental' acute psychosis with ecstasy use
14. Toxic effects of MDMA on central serotoninergic neurons in the primate: Importance of route and frequency of drug administration
15. Brain dopamine neurotoxicity in baboons treated with doses of methamphetamine comparable to those recreationally abused by humans: Evidence from [11c]WIN-35,428 positron emission tomographic studies and direct in vitro determinations
16. Methamphetamine-induced neurotoxicity alters locomotor activity, stereotypic behavior, and stimulated dopamine release in the rat
17. Evidence against an essential role of endogenous brain dopamine in methamphetamine-induced dopaminergic neurotoxicity
18. Positron emission tomographic evidence of toxic effect of MDMA (ecstasy) on brain serotonin neurons in human beings
19. Reduced striatal dopamine transporter density in abstinent methamphetamine and methcathinone users: Evidence from positron emission tomographic studies with [11c]WIN-35,428
20. Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers
21. Psicosis, antipsicóticos y primeros episodios en el trastorno bipolar
22. Trastornos psiquiátricos y consumo de éxtasis (MDMA): Una revisión de los casos publicados
23. Consideraciones especiales sobre pacientes esquizofrénicos con diagnostico dual y sus familiares
24. Cannabis and schizophrenia: A longitudinal study of cases treated in Stockholm County
25. A retrospective study of symptom patterns of cannabis induced psychosis
26. Cannabis and acute psychosis
27. Drug induced psychosis
28. Olanzapine
29. Olanzapine versus haloperidol treatment in first-episode psychosis
30. The brief psychiatric rating scale
31. A rating scale for depression
32. Validación de la escala de los síndromes positivo y negativo (PANSS) en una muestra de esquizofrénicos españoles
33. Depresión y manía
34. Multiple comparisons for repeated measures means
35. The BPRS: Psychometric developments
36. Clozapine for the treatment-resistant schizophrenic
37. A comparison of olanzapine with haloperidol in cannabis-induced psychotic disorder: A double-blind randomized controlled trial
38. Treatment of special populations with the atypical antipsychotics
39. Cocaine induced psychosis
40. A double-blind, controlled comparison of the novel antipsychotic olanzapine versus haloperidol or placebo on anxious and depressive symptoms accompanying schizophrenia